NO20053776L - Diagnostic imaging agents with MMP inhibitory activity - Google Patents

Diagnostic imaging agents with MMP inhibitory activity

Info

Publication number
NO20053776L
NO20053776L NO20053776A NO20053776A NO20053776L NO 20053776 L NO20053776 L NO 20053776L NO 20053776 A NO20053776 A NO 20053776A NO 20053776 A NO20053776 A NO 20053776A NO 20053776 L NO20053776 L NO 20053776L
Authority
NO
Norway
Prior art keywords
diagnostic imaging
inhibitory activity
imaging agents
pharmaceutical composition
matrix metalloproteinases
Prior art date
Application number
NO20053776A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053776D0 (no
Inventor
Alan Cuthbertson
Anthony Eamon Storey
Marivi Mendizabal
Sally-Anne Ricketts
Klaus Kopka
Hans-Jorg Breyholz
Stefan Wagner
Michael Schafers
Duncan Wynn
Julie Davis
Joseph Arukwe
Kirsty Heywood
Ian Wilson
Bodu Levkau
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0302891A external-priority patent/GB0302891D0/en
Priority claimed from GB0307524A external-priority patent/GB0307524D0/en
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of NO20053776D0 publication Critical patent/NO20053776D0/no
Publication of NO20053776L publication Critical patent/NO20053776L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20053776A 2003-02-10 2005-08-09 Diagnostic imaging agents with MMP inhibitory activity NO20053776L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0302891A GB0302891D0 (en) 2003-02-10 2003-02-10 Diagnostic imaging agents for cardiovascular disease
GB0307524A GB0307524D0 (en) 2003-04-01 2003-04-01 Diagnostic imaging agents with MMP inhibitory activity
PCT/GB2004/000524 WO2004069365A1 (fr) 2003-02-10 2004-02-10 Agents d'imagerie diagnostiques a activite inhibitrice de mmp

Publications (2)

Publication Number Publication Date
NO20053776D0 NO20053776D0 (no) 2005-08-09
NO20053776L true NO20053776L (no) 2005-09-30

Family

ID=32852413

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053776A NO20053776L (no) 2003-02-10 2005-08-09 Diagnostic imaging agents with MMP inhibitory activity

Country Status (8)

Country Link
US (1) US8231858B2 (fr)
EP (1) EP1592458A1 (fr)
JP (1) JP2006519216A (fr)
AU (1) AU2004210208B2 (fr)
CA (1) CA2514885A1 (fr)
NO (1) NO20053776L (fr)
RU (1) RU2005123801A (fr)
WO (1) WO2004069365A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0326546D0 (en) * 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
GB0421308D0 (en) * 2004-09-24 2004-10-27 Amersham Plc Enzyme inhibitor imaging agents
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
US8431909B2 (en) 2006-10-06 2013-04-30 Mallinckrodt Llc Self-aligning radioisotope elution system
EP2147684A1 (fr) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Agents de diagnostics sélectifs contre les métalloprotéases
EP2149568A1 (fr) 2008-07-22 2010-02-03 Bracco Imaging S.p.A Dimères arylsulfonamides en tant qu'inhibiteurs de métalloprotéases
US8809804B2 (en) * 2011-01-19 2014-08-19 Mallinckrodt Llc Holder and tool for radioisotope elution system
US9153350B2 (en) 2011-01-19 2015-10-06 Mallinckrodt Llc Protective shroud for nuclear pharmacy generators
US8866104B2 (en) 2011-01-19 2014-10-21 Mallinckrodt Llc Radioisotope elution system
US9023318B2 (en) * 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
WO2013010573A1 (fr) * 2011-07-18 2013-01-24 Universitaet Muenster Composés avec activité inhibitrice de métalloprotéinase de matrice
US20150023873A1 (en) 2011-11-11 2015-01-22 Lantheus Medical Imaging, Inc. Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging
EP2644601A1 (fr) * 2012-03-28 2013-10-02 Westfälische Wilhelms-Universität Münster Composés à activité inhibitrice de matrice-métalloprotéinase et agents d'imagerie de ceux-ci
GB202012671D0 (en) * 2020-08-13 2020-09-30 Nrf Ithemba Labs Theranostic Compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427646A (en) * 1981-04-02 1984-01-24 Research Corporation Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
WO1998050348A1 (fr) * 1997-05-09 1998-11-12 Agouron Pharmaceuticals, Inc. Inhibiteurs de metalloproteases, compositions pharmaceutiques les contenant et leurs utilisations pharmaceutiques
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US6989139B2 (en) * 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
EP1309579B1 (fr) * 2000-05-30 2005-10-12 Board Of Governors Of Wayne State University Inhibiteurs de metalloproteinases matricielles (mmp)

Also Published As

Publication number Publication date
AU2004210208A1 (en) 2004-08-19
US8231858B2 (en) 2012-07-31
EP1592458A1 (fr) 2005-11-09
AU2004210208B2 (en) 2007-06-07
US20070071670A1 (en) 2007-03-29
WO2004069365A1 (fr) 2004-08-19
WO2004069365A8 (fr) 2004-09-30
NO20053776D0 (no) 2005-08-09
RU2005123801A (ru) 2006-03-27
JP2006519216A (ja) 2006-08-24
CA2514885A1 (fr) 2004-08-19

Similar Documents

Publication Publication Date Title
NO20053776L (no) Diagnostic imaging agents with MMP inhibitory activity
MX2007011009A (es) Compuestos de piperidina 3,4,5-substituidos.
WO2004074434A3 (fr) Methodes et compositions permettant d'administrer des agents therapeutiques et diagnostiques
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BRPI0519443A2 (pt) composto orgÂnicos
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
BRPI0517803A (pt) pirazolpirimidinas 1,4-substituìdas como inibidores de cinase
SV2011003786A (es) Compuestos quimicos 251
WO2006044497A3 (fr) Composes de spiropiperidine utilises comme inhibiteurs de beta-secretase en vue du traitement de la maladie d'alzheimer
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
UY31180A1 (es) Derivados de (1r, 2r)-n-(1-cianociclopropil)-2-ciclohexanocarboxamidas sustituidas, procedimiento de preparación, composiciones faramacéuticas conteniéndolos y aplicaciones.
EA200801997A1 (ru) Новые соединения
WO2005075471A3 (fr) Composes thiazole utilises en tant qu'inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase de type 1
DK2157192T3 (da) Sammensætninger til diagnose og terapi af sygdomme forbundet med afvigende ekspression af futriner (R-spondiner)
WO2007006534A3 (fr) Composes organiques
BRPI0610205A2 (pt) piperidinas 3,4-substituìdas como inibidores da renina
NO20076053L (no) Pyrazolpyrimidinderivat for behandling og forebygging av leversykdom
WO2006074924A8 (fr) Tetrahydropyridines 3,4(,5) substituees
ATE384519T1 (de) Hemmer-darstellende mittel
DE602004030017D1 (de) Heterocyclische verbindungen als nützliche malonyl-coa decarboxylase-hemmer
NO20073631L (no) Metasubstituerte tiazolidinoner, fremgangsmate for fremstilling og anvendelse av disse som legemiddel
WO2006108680A3 (fr) Matieres et compositions pharmaceutiques destinees a inhiber les glyoxalases et utilisation de celles-ci pour lutter contre les protozoaires et les helminthes
UY29394A1 (es) Derivados sustituidos de n-(5-(2-propilamino.1.hidroxietil)-2-hdroxifenil) metano sulfonamida, composiciones farmacéuticas que lo contienen y aplicaciónes.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application